GMP Batch Release Testing

Good Manufacturing Practice (GMP) batch release testing—also known as lot release testing—is a critical step in ensuring the quality, safety, and consistency of pharmaceutical and biopharmaceutical products prior to their release for clinical use, commercial distribution, or export. These tests confirm that each production batch meets predefined specifications established in the product’s Marketing Authorisation (MA) or Clinical Trial Dossier (CTD).

Our contract analytical services teams provide comprehensive GMP-compliant release testing for active pharmaceutical ingredients (APIs), investigational medicinal products (IMPs), and finished pharmaceutical products. By leveraging a broad range of analytical technologies, we deliver responsive and reliable testing to support product release while maintaining full regulatory compliance.

batch_release
Comprehensive Analytical Capabilities

Our batch release testing programs incorporate chemical, physical, and biological analyses using validated methods aligned with major pharmacopeial standards, including BP, EP, JP, and USP. Advanced analytical technologies are applied to ensure thorough product characterization and specification compliance, including:

  • Chromatography-based techniques

  • Mass spectrometry

  • Spectroscopy

  • Biophysical characterization methods

These capabilities support release testing across a wide range of pharmaceutical products, including inhaled drug products, oligonucleotides, and biologics such as monoclonal antibodies, biosimilars, bispecific antibodies, and viral vectors.

Through integrated analytical expertise and robust quality systems, our teams help ensure that pharmaceutical and biopharmaceutical products meet regulatory standards for quality, safety, and efficacy prior to release.

Typical GMP Lot Release Testing Program

A comprehensive GMP lot release testing program encompasses multiple analytical areas to ensure product quality, safety, and consistency. Product identity is typically confirmed using techniques such as SDS-PAGE in combination with Western blotting or CE-SDS, along with isoform profiling through methods like isoelectric focusing (IEF or cIEF).

Assessment of biological activity is performed through a range of potency evaluations, including cell-based assays and, where appropriate, in vivo studies. These are often complemented by protein characterization and binding assays to further define functional properties.

Product purity and impurity profiles are evaluated using several orthogonal approaches. These commonly include analysis of residual host cell DNA and proteins, as well as chromatographic techniques such as size-exclusion (SEC), cation-exchange (CEX), and reverse-phase (RP) HPLC. Additional methods like CE-SDS and cIEF are also applied to monitor structural variants and impurities.

Key physicochemical attributes are measured to confirm formulation consistency, including pH and osmolality. Presentation-related characteristics are also examined, such as visual appearance, accurate fill volume in vials or syringes, and verification of excipient concentrations.

Microbiological quality is ensured through sterility testing and other microbiological assays. Endotoxin levels are typically assessed using the LAL assay or monocyte activation test, alongside evaluation of pyrogenicity in vivo when required. General safety testing, including abnormal toxicity assessments, may also be conducted as part of the overall release strategy.

Contamination Detection Assays and Analytical Services

Contamination testing plays a critical role in ensuring the safety of biopharmaceutical products, from early preclinical materials through bulk harvest evaluation of clinical and commercial batches. These assessments help confirm that products are free from unintended contaminants prior to use in both animal studies and human applications.

In addition, evaluation of the purification process—particularly its effectiveness in removing impurities—and the detection of residual materials from manufacturing steps are essential components of product characterization. These data form a key part of the Chemistry, Manufacturing, and Controls (CMC) section required for regulatory submissions.

Our contamination testing capabilities include a comprehensive suite of compendial assays designed to detect mycoplasma and bacterial contaminants, along with a range of viral detection methods spanning in vivo, in vitro, and biochemical approaches.

Our team works closely with clients to develop tailored contamination control strategies, selecting from established assays or designing customized solutions to meet specific product and process requirements. Testing can be applied across all stages of manufacturing to monitor and quantify process-related impurities, including residual Protein A, host cell DNA, surfactants such as Tween, and reagents such as IPTG, TRIS, and PEI, as well as endotoxins and host cell proteins.

Contamination Detection Capabilities

Our contamination detection services encompass a broad spectrum of analytical and microbiological testing approaches designed to support product safety and regulatory compliance. These capabilities include microbiology-based evaluations such as sterility and mycoplasma testing, as well as assessments of pyrogenicity through endotoxin assays and monocyte activation tests. Viral safety is addressed through a combination of classical and advanced methods, including next-generation sequencing for comprehensive detection of adventitious agents.

In addition to microbial and viral testing, we provide extensive impurity analysis. This includes host cell protein and residual DNA quantification, along with detailed characterization of process- and product-related impurities using techniques such as HPLC-ELSD, HPLC-CAD, HPLC-MS, and ELISA.

Supported by state-of-the-art instrumentation, our laboratory delivers thorough, client-specific analysis of both impurities and raw materials. We also offer method transfer, development, and validation services to implement customized, product-specific assays that align with individual program requirements.

Viral Safety Testing

A robust viral safety testing strategy is essential to ensure the safety of biologic products prior to their progression into clinical development and eventual market release. Regulatory frameworks require comprehensive evaluation to confirm the absence of adventitious viral contaminants throughout the manufacturing lifecycle.

Such testing is applied broadly across all relevant materials and stages of production. This includes starting materials used in biomanufacturing—such as cell banks, viral vectors, and virus seeds—as well as process intermediates like bulk harvests. In addition, biological raw materials are assessed, along with final biological products, including vaccines and cell and gene therapy products.

Viral safety testing relies on a range of analytical approaches to detect and, when required, quantify unintended viral contaminants in biological products. These approaches include in vitro cell-based assays, molecular techniques, and in vivo animal studies, each contributing complementary information on potential viral presence.

An effective viral safety program integrates these methodologies into a comprehensive framework that evaluates cell banks, raw materials, and manufacturing processes. This strategy incorporates both broad-spectrum detection methods and targeted assays for specific viruses, together with well-designed viral clearance studies to demonstrate that manufacturing processes can reliably remove or inactivate potential viral contaminants.

General Virus Detection Assays

A comprehensive suite of general virus detection methods is employed to identify potential adventitious viral contaminants across a wide range of sample types. In vitro adventitious agent testing, including both 14- and 28-day assays, is used to detect low-level viral contamination. These studies leverage a diverse selection of cell lines and virus systems, enabling assay conditions to be tailored to the specific characteristics of each sample.

Complementing in vitro approaches, in vivo adventitious agent testing is conducted to identify inapparent viruses that may not be detectable in cell culture systems. These assays utilize established animal models, including adult and suckling mice, embryonated eggs, and guinea pigs, to provide an additional layer of detection sensitivity.

Transmission electron microscopy (TEM) is also applied as a powerful tool for direct visualization and characterization of viral particles. Using GMP-compliant, validated digital TEM methods, analyses are performed on cell substrates and bulk harvest materials to assess retroviral burden and detect other adventitious viral or microbial contaminants.

In addition, next-generation sequencing (NGS) offers a highly sensitive and comprehensive approach for viral detection and genetic characterization. Conducted under GMP conditions, NGS-based methods enable broad-spectrum identification of known and unknown viruses, supported by advanced bioinformatic analysis. These technologies provide faster, more informative, and animal-free alternatives to traditional testing approaches, supporting informed decision-making in biologics development.

Specific Virus and Retrovirus Detection Assays

Targeted virus detection strategies are employed to identify specific viral contaminants associated with particular species or manufacturing materials. For example, assays designed for bovine and porcine viruses are performed in accordance with 9 CFR requirements, enabling compliant detection of viral agents in materials such as fetal bovine serum, porcine-derived enzymes (e.g., trypsin and pepsin), cell-free supernatants, cell lysates, and related products. In addition, serological screening approaches—including mouse, hamster, and rat antibody production tests (MAP, HAP, and RAP)—are utilized to detect rodent viruses.

Molecular methods further enhance detection capabilities through nucleic acid amplification techniques such as PCR and RT-PCR. Both quantitative PCR (qPCR) and droplet digital PCR (ddPCR) platforms are available for sensitive detection and, when required, quantification of RNA and DNA viruses. Broad-range assays targeting viral families such as adenoviruses, herpesviruses, papillomaviruses, and polyomaviruses can be applied, with options for customization based on specific project needs.

A range of specialized assays is also employed for retrovirus detection and characterization. These include XC plaque assays, which support both direct and extended formats for detecting and quantifying ecotropic murine leukemia viruses. S+L− focus assays are used either as standalone methods or as endpoints for other assays to identify xenotropic, amphotropic, and mink cell focus-forming murine leukemia viruses. Co-cultivation approaches are applied to amplify potential infectious retroviruses by growing test materials alongside susceptible cell substrates, increasing the likelihood of detection for low-level contaminants. Detection strategies may incorporate multiple endpoints, including PBRT and S+L− assays. In addition, PCR-based reverse transcriptase (PBRT) assays provide a sensitive molecular approach for identifying retroviral activity.

GMP Stability Testing Programs

Biopharmaceutical products—including proteins, peptides, viral vectors, and plasmids—are inherently sensitive to environmental conditions. Stability studies are therefore conducted to assess how these products respond to various factors such as temperature, humidity, and time. The data generated from these studies are used to define appropriate storage and shipping conditions for both drug substances and finished products, as well as to establish shelf life or retest intervals.

Evaluation of stability typically involves both real-time and accelerated study designs. In real-time testing, materials are stored under recommended conditions and monitored over an extended period until they no longer meet established specifications. Accelerated stability studies, by contrast, expose products to elevated stress conditions—such as increased temperature or humidity—to induce degradation more rapidly. These results, together with established relationships between degradation rates and stress factors, are used to model and predict product behavior under normal storage conditions.

In addition, forced degradation studies are employed to deliberately challenge product stability under extreme conditions, thereby accelerating breakdown processes. While the complex and often non-linear degradation kinetics of proteins limit the use of such studies for direct shelf-life prediction, they provide valuable insight into degradation mechanisms and pathways. As a result, forced degradation is especially useful during early development, where it supports formulation optimization and helps define conditions necessary to maintain product stability.

Advanced Analytical Methods Supporting Stability Testing

Stability studies are supported by a broad range of advanced, stability-indicating analytical techniques performed using modern instrumentation. These methods are selected to comprehensively evaluate structural integrity, purity, potency, and overall product quality throughout the study.

Protein characterization is carried out using electrophoretic techniques such as one- and two-dimensional SDS-PAGE, Western blotting, and isoelectric focusing. More detailed structural analysis is achieved through peptide mapping of proteins and peptides, typically using reverse-phase HPLC with UV and/or mass spectrometric detection. Additional chromatographic approaches—including reverse-phase, size-exclusion, ion-exchange, and hydrophobic interaction chromatography—are applied to monitor stability and detect degradation products.

Further analytical capabilities include sulfhydryl group analysis and detailed assessment of glycosylation profiles, including both N- and O-linked carbohydrate characterization. Capillary electrophoresis methods, such as cIEF, CE-SDS, and capillary zone electrophoresis (CZE), are also employed to evaluate charge and size heterogeneity.

Quantitative and physicochemical assessments include determination of protein concentration, spectrophotometric measurements (UV-Vis, fluorescence, and circular dichroism), as well as evaluation of pH, dissolution, appearance, and color. Formulation-specific attributes—such as subvisible particulate levels and moisture content—are also routinely analyzed.

Biological activity and potency are assessed using a range of assays, including ELISA-based methods, immuno-ligand assays, cell-based assays, in vivo models, and binding studies such as surface plasmon resonance (SPR). Additional testing includes total active ingredient quantification, container closure integrity, and microbiological evaluations such as endotoxin testing, microbial enumeration, and sterility assessment.

GMP Storage Conditions for Stability Studies

A wide range of GMP-compliant storage environments is maintained to support stability studies across diverse biopharmaceutical products. Cryogenic storage capabilities include liquid nitrogen (LN₂) freezers with a current inventory of seventeen 40K dewars, along with five additional dewars of varying sizes. The infrastructure is designed for scalability, allowing expansion to accommodate an additional twenty 40K dewars as program needs grow.

In addition to cryogenic storage, both walk-in and reach-in chambers are available to support ICH-compliant and custom-defined environmental conditions. Standard conditions include controlled temperature and humidity settings such as 25 °C/60% RH, 30 °C/65% RH, and 40 °C/75% RH, as well as temperature-only environments including 30 °C and 5 °C. Cold and ultra-low temperature storage options are also supported at −20 °C and −70 °C, ensuring appropriate conditions for a broad spectrum of stability study requirements.

Long-Term Stability Studies

Long-term stability studies for biopharmaceutical products are performed under the intended storage conditions to evaluate product performance over time. In parallel, shorter-duration studies at elevated temperatures are often conducted to support assessments of in-use stability and shipping conditions. Lower temperature storage is frequently incorporated to establish baseline, non-stressed reference data and to mitigate risk in the event that primary storage conditions prove suboptimal.

Our experienced team ensures that each stability program is designed and executed under conditions appropriate for the specific biologic, supporting reliable data generation and informed decision-making throughout the product lifecycle.

Technology Transfer

Effective management of technology transfer is essential for the successful and efficient implementation of a lot release testing program at a contract research organization (CRO). Our team engages with clients early in the process to review their methodologies and gain a thorough understanding of how their procedures are performed in practice.

This proactive approach enables rapid and accurate transfer of client methods to our facility, while ensuring consistent control and performance throughout the product lifecycle. Our expertise in technology transfer, combined with strong communication, comprehensive documentation, and robust study execution, allows us to support clients in a timely and efficient manner.

Actcell Labs Inc
1361 Amsterdam Ave.,
Floor 3, New York,
NY 10027, USA
+1 888 4880155
support@actcelllabs.com